Harris Baloch
Endocrinology, Diabetes & Metabolism · Montgomery, OHNPI 1487084802
Payments from drug & device makers
Across 66 payments — averaging $20.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$195
- Dexcom, Inc.$169
- BETA Bionics, Inc.$155
- Abbott$122
- Reflow Medical Inc$75
- Tandem Diabetes Care, Inc.$61
- plus $549 from 14 others
What the payments were for
- Food & beverage$1,327100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 14 | $195 |
| Dexcom, Inc. | 10 | $169 |
| BETA Bionics, Inc. | 7 | $155 |
| Abbott | 3 | $122 |
| Reflow Medical Inc | 1 | $75 |
| Tandem Diabetes Care, Inc. | 2 | $61 |
| Insulet Corporation | 3 | $60 |
| Lilly USA, LLC | 3 | $57 |
| AbbVie | 3 | $56 |
| Medtronic | 3 | $51 |
| Xeris Pharmaceuticals, Inc. | 3 | $49 |
| Boehringer Ingelheim | 2 | $48 |
| Corcept Therapeutics | 2 | $42 |
| Amgen | 2 | $36 |
| Ascensia Diabetes Care US Inc. | 2 | $33 |
| Tolmar, Inc. | 2 | $32 |
| Cequr Corporation | 1 | $31 |
| Bayer | 1 | $22 |
| Pfizer | 1 | $17 |
| Sequel Med Tech, LLC | 1 | $15 |
How this compares
$1,327 in reported general payments places this provider in the 45th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 411 | $458,089 |
| JardianceEmpagliflozin | 146 | $159,646 |
| OzempicSemaglutide | 120 | $126,053 |
| TrulicityDulaglutide | 33 | $38,528 |
| Teriparatide | 12 | $37,611 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 43 | $26,922 |
| FarxigaDapagliflozin Propanediol | 26 | $18,093 |
| JanuviaSitagliptin Phosphate | 13 | $17,609 |
| RybelsusSemaglutide | 16 | $16,732 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $14,166 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 27 | $10,993 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 79 | $10,961 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 30 | $10,486 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $4,704 |
| Novolog FlexpenInsulin Aspart | 28 | $3,921 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $57 | $497,937455 claims |
| Boehringer IngelheimJardiance | $48 | $159,646146 claims |
| Novo NordiskOzempic, Rybelsus | $195 | $142,786136 claims |
| AbbVieSynthroid | $56 | $3,13236 claims |
| PfizerLevoxyl | $17 | $36414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Montgomery
- Toby BriskinBedford$9.8M
- Charles SmithCanton$5.3M
- Kevin PantaloneCleveland$4M
- Elena ChristofidesColumbus$3.5M
- Arvind KrishnaCanton$3.1M
- Bartolome BurgueraCleveland$3.1M
- Steven IngColumbus$1.9M
- Kathleen DunganColumbus$1.4M
- Kyaw SoeColumbus$1.3M
- John PaesWesterville$671K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.